SEARCH

SEARCH BY CITATION

References

  • 1
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 2
    Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346355.
  • 3
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958965.
  • 4
    National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002-June 10-12, 2002. HEPATOLOGY 2002; 36(Suppl): S3S20.
  • 5
    Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. HEPATOLOGY 2003; 38: 645652.
  • 6
    Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL Jr, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43: 425433.
  • 7
    Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. HEPATOLOGY 2006; 43: 954960.
  • 8
    Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, Foucher J, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006; 131: 10401048.
  • 9
    Pawlotsky JM. Therapy of hepatitis C: from empiricism to eradication. HEPATOLOGY 2006; 43(Suppl): S207S220.
  • 10
    Pawlotsky JM, Gish RG. Future therapies for hepatitis C. Antivir Ther 2006; 11: 397408.
  • 11
    Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. HEPATOLOGY 2002; 36(Suppl): S65S73.
  • 12
    Pawlotsky JM. Molecular diagnosis of viral hepatitis. Gastroenterology 2002; 122: 15541568.
  • 13
    Chevaliez S, Pawlotsky JM. Use of virologic assays in the diagnosis and management of hepatitis C virus infection. Clin Liver Dis 2005; 9: 371382.
  • 14
    Chevaliez S, Pawlotsky JM. Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease. Int J Med Sci 2006; 3: 3540.
  • 15
    Beld M, Sentjens R, Rebers S, Weegink C, Weel J, Sol C, et al. Performance of the new Bayer Versant HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum: conversion to international units and comparison with the Roche Cobas Amplicor HCV Monitor, version 2.0, assay. J Clin Microbiol 2002; 40: 788793.
  • 16
    Germer JJ, Heimgartner PJ, Ilstrup DM, Harmsen WS, Jenkins GD, Patel R. Comparative evaluation of the Versant HCV RNA 3.0, Quantiplex HCV RNA 2.0, and Cobas Amplicor HCV Monitor version 2.0 assays for quantification of hepatitis C virus RNA in serum. J Clin Microbiol 2002; 40: 495500.
  • 17
    Morishima C, Chung M, Ng KW, Brambilla DJ, Gretch DR. Strengths and limitations of commercial tests for hepatitis C virus RNA quantification. J Clin Microbiol 2004; 42: 421425.
  • 18
    Elbeik T, Markowitz N, Nassos P, Kumar U, Beringer S, Haller B, et al. Simultaneous runs of the Bayer Versant HIV-1 version 3.0 and HCV bDNA version 3.0 quantitative assays on the system 340 platform provide reliable quantitation and improved work flow. J Clin Microbiol 2004; 42: 31203127.
  • 19
    Elbeik T, Surtihadi J, Destree M, Gorlin J, Holodniy M, Jortani SA, et al. Multicenter evaluation of the performance characteristics of the Bayer Versant HCV RNA 3.0 assay (bDNA). J Clin Microbiol 2004; 42: 563569.
  • 20
    Hendricks DA, Friesenhahn M, Tanimoto L, Goergen B, Dodge D, Comanor L. Multicenter evaluation of the Versant HCV RNA qualitative assay for detection of hepatitis C virus RNA. J Clin Microbiol 2003; 41: 651656.
  • 21
    Trimoulet P, Halfon P, Pohier E, Khiri H, Chene G, Fleury H. Evaluation of the Versant HCV RNA 3.0 assay for quantification of hepatitis C virus RNA in serum. J Clin Microbiol 2002; 40: 20312036.
  • 22
    Soler M, Pellerin M, Malnou CE, Dhumeaux D, Kean KM, Pawlotsky JM. Quasispecies heterogeneity and constraints on the evolution of the 5′ noncoding region of hepatitis C virus (HCV): relationship with HCV resistance to interferon-alpha therapy. Virology 2002; 298: 160173.
  • 23
    Caliendo AM, Valsamakis A, Zhou Y, Yen-Lieberman B, Andersen J, Young S, et al. Multilaboratory comparison of hepatitis C virus viral load assays. J Clin Microbiol 2006; 44: 17261732.
  • 24
    Germer JJ, Harmsen WS, Mandrekar JN, Mitchell PS, Yao JD. Evaluation of the Cobas TaqMan HCV test with automated sample processing using the MagNA pure LC instrument. J Clin Microbiol 2005; 43: 293298.
  • 25
    Konnick EQ, Williams SM, Ashwood ER, Hillyard DR. Evaluation of the Cobas Hepatitis C Virus (HCV) TaqMan analyte-specific reagent assay and comparison to the Cobas Amplicor HCV Monitor V2.0 and Versant HCV bDNA 3.0 assays. J Clin Microbiol 2005; 43: 21332140.
  • 26
    Sarrazin C, Gartner BC, Sizmann D, Babiel R, Mihm U, Hofmann WP, et al. Comparison of conventional PCR with real-time PCR and bDNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5. J Clin Microbiol 2006; 44: 729737.
  • 27
    Kuiken C, Combet C, Bukh J, Shin IT, Deleage G, Mizokami M, et al. A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes. HEPATOLOGY 2006; 44: 13551361.